Stock data
Fate Therapeutics, Inc. (FATE)
Fate Therapeutics, Inc. (FATE) reported revenue of US$6.65M and net income of -US$136.31M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | US$6.65M | — | -US$147.70M | -US$136.31M | — |
| 2024 | US$13.63M | — | -US$210.28M | -US$186.26M | — |
| 2023 | US$63.53M | — | -US$190.51M | -US$160.93M | — |
| 2022 | US$96.30M | — | -US$308.39M | -US$281.72M | — |
| 2021 | US$55.85M | — | -US$216.99M | -US$212.15M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | US$2.08M | -US$30.16M | — |
| 2026-03-31 | US$1.30M | -US$31.21M | — |
| 2025-12-31 | US$1.37M | -US$32.37M | — |
| 2025-09-30 | US$1.74M | -US$32.25M | — |
| 2025-06-30 | US$1.91M | -US$34.07M | — |
| 2025-03-31 | US$1.63M | -US$37.62M | — |
| 2024-12-31 | US$1.86M | -US$52.15M | — |
| 2024-09-30 | US$3.07M | -US$47.68M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.